BIOGEN IDEC PROVIDES UPDATE ON ZEVALIN TRIAL

A A

Biogen Idec has announced that new data demonstrate that patients may benefit from earlier and consolidated use of Zevalin (ibritumomabtiuxetan) radioimmunotherapy in refractory and hard-to-treat cancers, including diffused large B-cell lymphoma (DLBCL), mantle cell lymphoma, and follicular non-Hodgkin's lymphoma.

The Phase II study is exploring the feasibility and effectiveness of first-line use of Zevalin and standard rituximab-plus-chemotherapy (R-CHOP) in older patients with high-risk DLBCL, a disease that represents approximately one-third of all lymphomas and primarily impacts people over 60 years of age.

Patients received R-CHOP chemotherapy at standard doses forinduction therapy. After hematologic recovery and R-CHOP restaging, patients were eligible for Zevalin, which was given six to nine weeks post-R-CHOP.

No patients receiving the full treatment regimen of Zevalin and R-CHOP relapsed, with 21-month median follow-up. In addition, sequential R-CHOP followed by Zevalin was associated with manageable toxicities.